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Background
The inability to target cancer stem cells (CSC) may be a
significant factor contributing to treatment failure.
Novel therapeutic strategies are needed to immunologi-
cally target CSCs.
Methods
We have developed a strategy to target the CSC popula-
tions in melanoma and squamous cell carcinoma using
CSC lysate-pulsed dendritic cells (DC). D5 is a poorly
immunogenic clone of the melanoma cell line B16 syn-
geneic to B6 mice. In minimal tumor model, B6 mice
were inoculated subcutaneously with D5 cells. The 1st
vaccine was administered 24 hours after tumor inocula-
tion for treatment, followed by a 2nd vaccine on day 8.
At the end of the experiments, the lungs were harvested
and fixed with 10% formalin, paraffin embedded and
stained with H&E to observe the histo-pathological
alterations under the microscope. Freshly harvested pri-
mary subcutaneous tumors were disaggregated into sin-
gle cell suspensions. Tumor cells were incubated with
PE-anti-CCR7 and CCR10 or isotype controls. The cells
were then resuspended in 2% formalin for flow cytometry
analysis. The mRNA levels of chemokine CCL21, CCL27
or CCL28 in lung tissues were analyzed using real time
quantitative PCR (qRT-PCR). Sorted ALDHlow or ALDH-
high D5 cells were incubated with the immune superna-
tants collected from the cultured B cells with equal
quantity of IgG followed by incubation with the 2nd anti-
body FITC-conjugated anti-mouse IgG. The binding of
supernatant antibody to ALDHlowvs. ALDHhighD5 cells
was assessed using flow cytometry. Survival analysis was
determined by the log-rank test. Analysis for the presence
of lung metastasis was performed using the Fisher exact
test. Other data were evaluated by unpaired Student’s
t-test (2 cohorts) or one-way analysis of variance
(ANOVA) (> 2 cohorts). A two-tailed P value
Results
Using mouse models we demonstrate that DC pulsed
with CSCs enriched by virtue of their expression of the
CSC marker ALDH (CSC-DC) significantly inhibited
local tumor growth, reduced development of pulmonary
metastases and prolonged survival in the minimal tumor
models. The effect was associated with down regulation
of CCR7 and CCR10 in tumor cells and decreased
CCL27 and CCL28 expression in lung tissue. CSC-DC
vaccine significantly reduced ALDHhigh CSCs. Direct
targeting of CSCs was demonstrated by specific binding
of IgG produced by ALDHhigh CSC-DC vaccine-primed
B cells to ALDHhigh CSCs, resulting in lysis of these tar-
get cells in the presence of complement. When adminis-
tered in the adjuvant setting after surgical excision of
the SCC7 bulk tumor mass, administration of SCC7
CSC-DC vaccine reduced development of local tumor
recurrence as well as systemic disease and prolonged
survival demonstrating the efficacy of this approach.
Conclusions
These data suggest that the CSC-DC vaccine approach
may be useful in the adjuvant setting where local and
systemic relapse are high after surgery.
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